Mark Litton, Athira Pharma CEO
September 6, 2022 10:58 AM EDTUpdated 04:56 PM
R&D
FDA+

Up­dat­ed: Athi­ra plots an Alzheimer's come­back af­ter scan­dal, PhII fail — and hints at pos­si­ble ac­cel­er­at­ed ap­proval pitch

Max Gelman

Senior Editor

Athi­ra Phar­ma built up high hopes for its al­ter­na­tive ap­proach to de­vel­op­ing Alzheimer’s treat­ments, but a scan­dal in­volv­ing doc­tored im­ages, a very pub­lic …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times